Vera Therapeutics announces atacicept Phase 3 data: 46% proteinuria reduction, 42% vs placebo (p<0.0001)

Vera Therapeutics, Inc.

Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
Secondary endpoints: Gd-IgA1 reduced by 68%; hematuria resolved in 81% of participants with baseline hematuria.
Safety profile favorable: serious adverse events 0.5% (atacicept) vs 5% (placebo); no deaths in either group.
eGFR results not disclosed per FDA recommendation to sponsors of IgAN registrational trials.
Data presented at ASN Kidney Week and simultaneously published in The New England Journal of Medicine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.